# Innovative Automated Insulin Delivery System for Type 2 Diabetes

Study · id `cardio:ct-nct06853990` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06853990](<https://clinicaltrials.gov/study/NCT06853990>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06853990

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 307 participants.

## Technical summary

Registry record NCT06853990. Allocation not applicable; no masking; primary purpose treatment. Start 2025-04-14 (actual); primary completion 2026-02-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 307 participants (enrolled count; ClinicalTrials.gov record NCT06853990, source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)
- Started: 2025-04-14 (actual) (ClinicalTrials.gov record NCT06853990, source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)
- Primary completion: 2026-02-25 (actual) (ClinicalTrials.gov record NCT06853990, source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)
- Completion: 2026-05-06 (actual) (ClinicalTrials.gov record NCT06853990, source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06853990, source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06853990-2026-06-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Innovative Automated Insulin Delivery System for Type 2 Diabetes
- Acronym: twiist-T2D
- Condition: Type 2 Diabetes
- Condition: Insulin Treated Type 2 Diabetes Mellitus
- Intervention (Device): twiist insulin delivery system
- Lead sponsor: Deka Research and Development
- Lead sponsor class: INDUSTRY
- Collaborator: Sequel Med Tech
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 1cc7fb1e674103c84f4571ee4575f2023a915acadd1698094293064a3a764b8f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
